

Edwyn Cruz-López, MD, PhD
Rotterdam, Netherlands

Postdoctoral Researcher at Erasmus MC, Erasmus University Rotterdam, specializing in the development of novel antihypertensive therapies for metabolic diseases such as hypertension and diabetes. His work focuses on liver-targeted siRNA therapies, mechanisms of siRNA reversal, and comparative analysis of drug classes and combinations – including angiotensinogen siRNA, SGLT2 inhibitors, ARBs, and ACE inhibitors – to improve cardiovascular and renal outcomes. His research, published in leading journals, aims to translate cutting-edge science into innovative therapeutic strategies. He is a member of the European Society of Hypertension, the American Heart Association, and the International Renin-Angiotensin-Aldosterone Conference (IRAAC).